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Abstract In children and adolescents with conduct dis-
order (CD), pharmacotherapy is considered when non-
pharmacological interventions do not improve symptoms
and functional impairment. Risperidone, a second-genera-
tion antipsychotic is increasingly prescribed off-label in
this indication, but its efficacy and tolerability is poorly
studied in CD, especially in young people with normal
intelligence. The Paediatric European Risperidone Studies
(PERS) include a series of trials to assess short-term effi-
cacy, tolerability and maintenance effects of risperidone in
children and adolescents with CD and normal intelligence
as well as long-term tolerability in a 2-year pharmacovig-
ilance. In addition to its core studies, secondary PERS
analyses will examine moderators of drug effects. As PERS
is a large-scale academic project involving a collaborative
network of expert centres from different countries, it is
expected that results will lead to strengthen the evidence
base for the use of risperidone in CD and improve stan-
dards of care. Challenging issues faced by the PERS con-
sortium are described to facilitate future developments in
paediatric neuropsychopharmacology.
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Introduction
The prescription of psychotropic medication is becoming
an increasingly important component of comprehensive
treatment programmes of child and adolescent psychiatric
disorders. However, most psychotropic medications have
not yet been approved for use in children or adolescents, or
are only approved for a minority of indications or specific
populations. One class of psychotropic medication that is
increasingly being prescribed to children and adolescents is
the second-generation antipsychotics (SGAs). Within this
class, risperidone is the most frequently prescribed drug in
children and adolescents across most countries [1–3]. In the
US, the number of children receiving SGAs increased by
62 % between 2002 and 2006, especially in those with
attention deficit/hyperactivity disorder and conduct disor-
der [4]. Data from the US National Ambulatory Medical
Care Surveys between 2005 and 2009 show that disruptive
behaviour disorders were the most common diagnoses in
both child and adolescent visits where an antipsychotic was
prescribed, counting for 63.0 and 33.7 %, respectively [5].
In the UK, the prescribing prevalence of antipsychotics for
patients 7–12 years of age in general practises almost tri-
pled between 1992 and 2005 with SGA prescribing
increasing 60-fold from 1994 to 2005 [6]. In the Nether-
lands, prescribing prevalence of antipsychotics doubled
from 1997 to 2005 with the highest prevalence being
among 10- to 14-year olds, and especially among boys [7].
This increased prevalence was mainly attributable to both
increased use of SGAs and a longer duration of use, which
clearly increases the exposure of this young population to
incompletely understood risks [8, 9].
These increased prescription rates of risperidone and
other SGAs for children and adolescents, particularly for
non-psychotic conditions, the off-license status of many of
these prescriptions, their metabolic side effects and the
inadequacy of long-term surveillance have raised concern
about uncritical prescriptions [2, 10, 11]. This context also
provided the impetus for the development of the Paediatric
European Risperidone Studies (PERS) research programme
that was awarded funding by the EU 7th framework in
response to the call HEALTH-2009-4.2-1: ‘‘Adapting off-
patent medicines to the specific needs of paediatric popu-
lations’’. PERS focuses on the use of risperidone in chil-
dren and adolescents with CD, and its key objective is to
perform a series of clinical studies, underpinned by a
Paediatric Investigation Plan (PIP) that will provide suffi-
cient information for a Paediatric Use Marketing Authori-
sation (PUMA) to be obtained for the use of risperidone in
CD in children and adolescents. A PUMA is a dedicated
marketing authorisation for medicinal products indicated
exclusively for use in the paediatric population. PUMAs
were introduced by the European Medicines Agency to
encourage the development of paediatric medicines. (http://
www.ema.europa.eu/ema/index).
In this paper, we describe the rationale of the PERS
studies, which include non-commercial clinical trials and
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an observational study on the efficacy and safety of ris-
peridone in children and adolescents with CD and without
intellectual disability.
Conduct disorder
Conduct disorder is a clinically heterogeneous disorder
defined by a pattern of repetitive and persistent antisocial
behaviours serious enough to violate the basic rights of
others or to exceed age-appropriate societal norms or rules.
Three-month prevalence rates of DSM-IV-TR defined CD
averaged 1.2 % in girls and 4.2 % in boys in a large lon-
gitudinal cohort study from the US [12] and the prevalence
of CD was 2.7 % in a representative sample of 5- to
16-year olds in Great Britain [13]. CD is a matter of sig-
nificant public health and societal concern because of
strong associations with adverse scholastic and work per-
formance, disrupted peer and family relationships, exces-
sive risk-taking behaviours which often result in personal
injury, loss of property, alcohol, nicotine and substance
abuse, accident proneness and development of later anti-
social personality disorder [14, 15]. In addition, CD has
also been associated with multiple service use [13].
The treatment of CD rests primarily on reducing the
number and severity of aggressive behaviours perpetrated
by patients with CD. Pharmacotherapy is usually not the
first line of treatment but is considered in those subjects
who have failed to respond to other interventions. Potential
non-pharmacological treatments include psychosocial/
behavioural interventions such as cognitive therapy or
social learning family interventions, e.g. parent manage-
ment training [16–18]. The pharmacological options for the
treatment of CD can be categorised into psychostimulants
(mostly in cases with attention deficit hyperactivity disor-
der—ADHD), antipsychotics, mood stabilisers and various
other less-used treatments such as a2 receptor agonists and
b-blockers [19].
Risperidone efficacy in children and adolescents
with CD
The US Food and Drug Administration (FDA) approved
risperidone in children and adolescents in the following
indications: (1) treatment of schizophrenia in adolescents,
ages 13–17; (2) short-term treatment of bipolar mania
associated with manic or mixed episodes of bipolar I disorder
in children and adolescents aged 10–17; (3) irritability
associated with autistic disorder in children and adolescents
aged 5–17 (Risperdal prescribing information http://www.
accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
In Europe, risperidone has been approved for the short-
term treatment (6 weeks) of aggression in CD in children
from the age of 5 and adolescents with sub-average intel-
lectual functioning or mental retardation (details in: http://
www.ema.europa.eu/docs/en_GB/document_library/Refer
rals_document/Risperdal_30/WC500007979.pdf).
The efficacy of risperidone in the disruptive behaviour
disorders [a broad category including CD, oppositional
defiant disorder (ODD), and also disruptive behaviour
disorder—not otherwise specified] and aggression has
mostly been studied in sub-average IQ children and ado-
lescents. A summary of randomised controlled trials of
risperidone in children and adolescents with these disorders
and aged 5–18 is shown in Table 1. A meta-analysis of two
of the above studies using the conduct problem sub-score
of the Nisonger Child Behaviour Rating Form showed a
mean difference of -8.61 (95 % CI -11.49, -5.74) judged
likely to be clinically significant [20].
A pooled analysis of nine RCTs of atypical antipsy-
chotics that measured aggressive behaviour examined a
total of 875 subjects (mean age = 9.2 years) [21]. On
average, study length was 45.7 days and the mean dose of
risperidone was 0.04 mg/kg/day. Effect sizes were gener-
ally large (mean ES = 0.9) and increased with study
duration. Risperidone was associated with greater effect
sizes than other medication classes such as mood stabilis-
ers, stimulants, antidepressants and a2 agonists.
To determine the long-term effectiveness of risperidone for
severe disruptive behaviours in children, 504 patients were
enrolled into in a multisite, 1-year, open-label study of patients
aged 5–14 years with disruptive behaviours and sub-average
intelligence [22]. Seventy-three percent of those enrolled
completed the study and the mean dose of risperidone was
1.6 mg/day. Scores on the Nisonger Child Behaviour Rating
Form Conduct Problem Scale improved significantly as early
as week 1, and improvement was maintained throughout the
trial (p \ 0.001 at each time point).
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A small subsample of patients (48 patients), who had
previously completed the 1-year open-label study of ris-
peridone, was followed-up for an additional year of treat-
ment [23]. The efficacy benefits from the original study
were maintained over the course of this extension study.
The above data support the short-term efficacy of ris-
peridone in children with sub-average IQ, but evidence is
limited in adolescents and youngsters with normal intelli-
gence. Long-term efficacy of risperidone has only been
documented in children with sub-average IQ or mixed
samples. Moreover, the potential impact of ADHD on
treatment response is unknown; ADHD status has not been
specified in the majority of the above studies. The same is
true for psychosocial interventions, also likely to affect
treatment outcome.
Risperidone safety in children and adolescents with CD
The paediatric population may be more vulnerable to
metabolic, endocrine, and extrapyramidal adverse effects
of SGAs than adults [24]. The Canadian Alliance for
Monitoring Effectiveness and Safety of Antipsychotics in
Children (CAMESA) guidelines group analysed 57 articles
on the use of risperidone in children and adolescents [25].
Main adverse effects found when comparing patients
receiving risperidone with those on placebo were the fol-
lowing: (1) higher mean weight gain with a mean differ-
ence of 2.09 kg in randomised controlled trials (RCTs)
lasting 6 months, (2) higher odds of extrapyramidal side
effects (OR 3.55, p \ 0.00001), (3) elevated prolactin
levels at endpoint in RCTs 12 weeks or less (with a mean
difference of 899.99 pmol).
Open-label studies showed continuous weight gain and
BMI increase; treatment of children during 45 weeks has
lead to a total mean weight gain of 7.2 kg with risperidone,
16.2 kg with olanzapine and 9.5 kg with clozapine [26]. A
large, prospective, open-label, non-randomised study in
youths aged 4–19, naive to antipsychotic medications, and
treated for almost 11 weeks, showed a weight gain equal or
above 7 % in 64.4 % of patients with risperidone, in
84.4 % receiving olanzapine, in 58.4 % with aripiprazole
and in 0 % comparison subjects [27]. In a recent review,
Number Needed to Harm (NNH) for weight gain with
Table 1 Summary of short-term randomised controlled trials of risperidone in disruptive behaviour disorders in children and adolescents 5 years
and above
Reference Sample
(age)
IQ
Duration Dose (mg/day) Primary outcome
Mean change (SD)
placebo/risperidone (p)
Effect size
Findling 2000 N = 20 (5–12) 10 weeks 0.75–1.5 RAAPP
IQ [ 70 -0.16 (0.54)/-1.65 (0.40) (p = 0.03)
Buitelaar 2001 N = 38 (12–18) 6 weeks 2.9 CGI-S
IQ 60–90 (p \ 0.01)
Van Bellinghen 2001 N = 13 (6–18) 4 weeks 1.2 ABC irritability (not prespecified)
IQ 45–85 0.1 (9.4)/-10.8 (6.05) (p \ 0.05)
Aman 2002 N = 118 (5–12) 6 weeks 1.16 NCBRF-CP
IQ 34–84 -6.2 (11.2)/-15.2 (10.6) (p \ 0.001)
-0.82
Snyder 2002 N = 110 (5–12) 6 weeks 0.98 NCBRF-CP
IQ 36–84 -6.8/-15.8 (p \ 0.01)
-0.73
Reyes 2006 N = 335 (5–17) 6 months \50 kg 0.81 Time to symptom recurrencea
216 with IQ [ 84 [50 kg 1.22 Symptom recurrence in 25 %: 37 versus
119 days (p \ 0.001)119 with IQ \ 84
Armenteros 2007 N = 25 (7–12) 28 days 1.08 CAS-P and CAS-T C 30 % change
IQ [ or = 75 CAS-P total: 77 %/100 % (p \ 0.5)
All with ADHD CAS-T total: 54 versus 27 % (NS)
No differences in mean CAS scores.
RAAPP rating of aggression against people and/or property scale, CGI-S Clinical Global Impression-Severity, NCBRF-CP Nisonger Child
Behaviour Rating Form conduct problem subscale, CAS-P Children’s Aggression Scale-Parent, CAS-T Children’s Aggression Scale-Teacher, NS
non significant
a Deterioration of two points or more on the Clinical Global Impression-Severity or seven points of more on the conduct problems subscale
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risperidone was estimated between 7 and 8 in children and
adolescents [28].
In a combined dataset from five clinical trials in 5- to
15-year-old children treated with risperidone, serum pro-
lactin showed a raise with a peak observed after 2 months
of treatment, followed by a gradual return to normal levels
after 5 months [29], but other studies have shown persis-
tence of high levels of prolactin in subjects treated with
risperidone 1 year or more [30]. In a pubertal sample of
males aged 10–20, receiving long-term risperidone (mean
duration 52 months), hyperprolactinemia was present in 47
versus 2 % in those without treatment and 14 versus 0 %
reported sexual dysfunction [31]. Clinical consequences of
the increase of prolactin levels are inconsistent across
studies and effects may vary with dose, treatment duration
and the pubertal status of patients [32].
The analysis of a series of placebo-controlled studies
showed that risperidone induced extrapyramidal effects in
a variable percentage of patients between 8 and 26 %.
NNH for tremor, dyskinesia or other extrapyramidal
symptoms varied from 6 to 33 % for risperidone according
to dose and duration [28]. A recent meta-analysis reported
higher odds of extrapyramidal symptoms in children trea-
ted with risperidone (OR 3.55; 95 % CI 2.04-5.48) and in
those treated with aripiprazole (OR 3.70; 95 % CI
2.37–5.77) compared with placebo. Sedation is another
commonly reported adverse effect of risperidone, mostly
occurring at the start of treatment or at after a dose
increase. Reported NNH for sedation, somnolence or
drowsiness varies between 2 and 5 [28].
Currently, there are insufficient data available about the
long-term safety of risperidone in children and adolescents.
The majority of safety studies have been limited to 1 year,
while treatment in clinical practice is typically for longer
periods. This is particularly important as the long-term use
of risperidone is not without health risks and is associated
with several potential adverse reactions, of which weight
gain and associated metabolic disruption are perhaps the
most worrisome.
Aims and objectives of PERS
The PERS clinical trials will focus on the investigation of
short-term efficacy, safety/tolerability and maintenance
effects of risperidone in the treatment of children and
adolescents with CD and normal intelligence, since in this
patient population risperidone has not systematically been
studied. Another focus of PERS is the long-term safety that
will be assessed in an observational pharmacovigilance
study, regardless of indication and patient characteristics.
As a first step, we developed a clinical trial strategy and
submitted a number of specific questions to the European
Medicine Agency (EMA) on the potential design of the
studies, the choice of the pivotal measures and their
potential impact for granting a Paediatric Use Marketing
Authorisation. These recommendations as well as those
from the EMA on the Paediatric Investigational Plan (PIP)
application were incorporated into the current trial proto-
cols. Close collaboration has been established with a
manufacturer of risperidone and a contract research orga-
nisation that will be able to implement and monitor clinical
psychopharmacology studies in this age group on a Euro-
pean level. PERS will also address a number of secondary
exploratory questions that will be discussed below.
Clinical trials in PERS
PERS consist of three related clinical studies, a short-term
efficacy and safety study, a study on maintenance effects,
and an open-label observational study. The three study
designs including details regarding clinical and/or labora-
tory parameters are outlined in detail as part of the Sche-
dule of Events (SOE; Annex 1).
Short-term efficacy of risperidone in CD: conduct
disorder in children and adolescents (CONCA)
CONCA is a multicentre, randomised, double-blind, par-
allel, placebo-controlled trial. This RCT will examine
whether risperidone, given orally in a dose of 0.25–3.0 mg/
day for 12 weeks, is superior to placebo in reducing dis-
ruptive behavioural symptoms of children and adolescents
with CD without mental retardation. CONCA comprises
three study periods and aims to enrol 264 patients (50 %
children 5- to 11-years old and 50 % adolescents
12–17.5 years). The sample size calculations were based
on an assumption of an effect size of 0.4 and 90 % power
with a 1:1 randomization scheme to risperidone or placebo.
The clinical diagnosis of CD according to DSM-IV-TR will
be confirmed by a structured interview (Kiddie-SADS,
conduct disorder module [33] and a score C27 on the
ODD/CD composite score of the Nisonger CBRF will be
required at Visits 2 or 3 to meet criteria of sufficiently
severe CD). Children and adolescents with ADHD and
those on stable stimulant medication, with no planned
changes during the trial, will not be excluded (see sup-
plementary material in Annex 1 for details of inclusion and
exclusion criteria).
Study Period I is a 2-week screening and washout per-
iod; during this period, patients will be screened for study
eligibility. Randomization to risperidone or placebo will
occur at Visit 3. Subjects will randomly be assigned to
risperidone or placebo in a 1:1 ratio and randomisation will
not be stratified. Study Period II is a 12-week acute
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treatment period (Visits 3–9). In order to safeguard patients
in the study, patients can be either in outpatient or inpatient
settings. For patients in the risperidone treatment group,
medication will be given in the evening and dosing will
begin at either 0.25 (\50 kg body weight) or 0.5 (C50 kg),
mg/day (tablets), depending on the patient’s weight. Doses
will be increased by 0.25 mg/day or 0.5 mg/day increments
each week to maximum doses that vary by patient weight
(\50 kg or C50 kg), based on the investigator’s assess-
ment of efficacy and tolerability/safety. Study Period III is
a 1-week double-blind period, a progressive withdrawal
from study medication (Visits 9–10).
Efficacy is measured by the last observation carried
forward (LOCF) mean change from baseline to endpoint on
the pivotal scale, the NCBRF–Typical IQ Version [34].
The primary measure is the ODD/CD Disruptive Behaviour
Composite Total score using investigator ratings based on
all available information. The decision to use an investi-
gator-rated NCBRF in the PERS studies is due to regula-
tory reasons (i.e. because in registration trials there is a
strong preference for a primary outcome based on profes-
sional/clinical assessment rather than an assessment by
parents, patients or teachers).
Secondary objectives of the study are to examine
whether treatment with risperidone is associated with
lower symptoms on the Clinical Global Impression:
Improvement and Severity scales (CGI-I and CGI-S [35],
the Modified Overt Aggression Scale (M-OAS [36, 37]),
and with better functioning on the Child-Global Assess-
ment Scale (C-GAS [38]), the CHIP-CE Parent Report
Form [39] and the Positive Social subscale of the Ni-
songer CBRF Typical IQ version [34]. We will also
assess the effect of risperidone on concurrent ADHD
symptoms using the ADHD-Rating Scale [40] and
examine whether ADHD and its treatment influence the
risperidone effect on disruptive behaviours.
We plan to further assess the effect of risperidone
compared to placebo on cognitive functioning (e.g. due to
possible sedative effects) using attentional and set-shifting
tests from the Amsterdam Neuropsychological Test battery
(ANT) [41]. Safety and tolerability will be assessed
extensively and include spontaneously reported and
investigator-rated treatment-emergent adverse events based
on information from both patient and parents. Measures
comprise potential extrapyramidal symptoms (Barnes
Akathisia Scale [42], Simpson-Angus Scale [43], Abnor-
mal Involuntary Movement Scale (AIMS) [35]); changes in
ECG, vital signs, body temperature, and laboratory analy-
ses; changes in growth, assessed using height, weight, and
body mass index (BMI); and changes in suicidal ideation
and suicidal behaviour, as assessed by the investigator-
rated Columbia Suicide Severity rating Scale (C-SSRS)
[44].
Maintenance effects in CD: discontinuation for conduct
disorder in children and adolescents (DIS-CONCA)
DIS-CONCA is a multicentre, randomised, double-blind,
parallel, placebo-controlled discontinuation (relapse pre-
vention) trial in children and adolescents, aged 6–17.5,
with CD and without mental retardation. The study incor-
porates a screening phase, an open-label period of treat-
ment with risperidone followed by randomization to
continued risperidone or placebo substitution over a
12-week period. This allows for an evaluation of rates of
relapse following response, and it is an accepted method
for determining the value of differing lengths of continu-
ation treatment following an initial response.
DIS-CONCA will examine whether risperidone given
orally in a dose of 0.25–3.0 mg/day is superior to placebo
in preventing relapse of symptoms of CD, as assessed
through a 12-week, double-blind discontinuation trial.
Inclusion criteria are similar to those for CONCA, and the
pivotal scale is as in CONCA the NCBRF–Typical IQ
Version-ODD/CD disruptive behaviour Composite Total
score [34] using investigator ratings based on all available
information. Since compliance is often poor in CD children
and adolescents, significant non-compliance [missing more
than two consecutive days of study medication (full doses),
or failure to take at least 70 % of prescribed doses of study
medication (full doses) during two or more visit intervals]
will be discussed with patient and parent and the patient
will be discontinued only when, in the opinion of the
investigator, the patient is deemed unlikely to become
compliant and data obtained from the patient judged
unreliable.
Clinical response is defined as [25 % reduction from
baseline score on the NCBRF-TIQ D-Total subscale at
endpoint and a score of 1 or 2 (‘‘much’’ or very much’’
improved) on the CGI-Improvement scale. The primary
efficacy measure will be comparison of the number of days
from randomization to relapse for each treatment group
using the Kaplan–Meier product limit estimator. Relapse is
defined as a deterioration of[2 points on the CGI-Severity
scale and a 25 % increase in the score on the Nisonger
pivotal scale, compared to start of Study Period II (average
of Visits 7 and 8), for at least two consecutive visits,
15 days apart.
Secondary objectives of DIS-CONCA are to establish
the long-term efficacy of treatment with risperidone on
secondary measures as the CGI-S, C-GAS, and Overt
Aggression Scale (OAS) and several measures of func-
tioning as the Child-Global Assessment Scale (C-
GAS;[57]), the CHIP-CE Parent Report Form [6] and the
‘Positive Social’ subscale of the Nisonger CBRF Typical
IQ version [1]. Further, we will assess the long-term effects
of risperidone on cognitive functioning and on ADHD
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symptoms, and collect extensive data on safety and
tolerability.
Participants will undergo four study periods. After
screening (Study Period I), Study Period II will be a
16-week titration and open-label treatment period (7 visits).
This acute treatment period was chosen to increase the
chance to reflect the change based on medication treatment.
All patients who complete Study Period II and maintain
clinical response are eligible to participate in Study Period
III. Two consecutive positive evaluations that meet the
criteria for response are required to enter into the ran-
domised discontinuation phase. Study Period III will be a
12-week double-blind, randomised, placebo-controlled
discontinuation period (8 visits). At the start of Study
Period III, patients will be randomised to continued ris-
peridone or placebo (1:1 ratio). In the placebo-discontin-
uation group, risperidone gradual discontinuation will be
started during the first 4 weeks of Study Period III, but the
specific timing of starting the discontinuation will be
unknown to patients, their families and the investigators.
Patients who meet relapse criteria during Study Period III
will be considered completers and may be discontinued and
given the opportunity of entering the observational pro-
spective study. Therefore, no interim analysis to stop the
study prematurely has been planned in the discontinuation
phase. After 24 weeks, medication will be discontinued in
2 weeks in all the non-relapsing patients (Study Period IV);
patients will have their final clinical assessment after fur-
ther 2 weeks, with the opportunity of entering, if appro-
priate, the observational prospective study.
Based on power calculations on previous studies with
risperidone in CD with mild mental retardation, 150 (50 %
children 6–11, 50 % adolescents 12–17.5) patients should
be enrolled in Study Period II. A sample size of 150 using a
1:1 randomization over risperidone and placebo will have
80 % power to detect an increase in relapse rate from
33.3 % in the risperidone group to 66.6 % in the placebo
group, using a proportional hazards analysis with a cen-
soring of data following a uniform distribution between the
6th and the 12th week (simulations, functionspower, li-
braryHmisc, R software 2.14). Considering that 25 % of
patients enrolled in Study Period II will not meet inclusion
criteria to continue in Study Period III, 200 patients should
be enrolled in Study Period II.
Observational pharmacovigilance study
There is a lack of knowledge about which factors make some
children and adolescents more vulnerable than others to the
short-term and long-term adverse effects of risperidone [8,
45–47]. Dose may be one obvious mediator, but many
available studies did not obtain risperidone plasma concen-
trations. Some recent evidence has suggested that genetic
factors that may also influence the occurrence of metabolic
or endocrine side effects such as weight gain and hyperpro-
lactinemia, but much remains to be investigated in this area
[48, 49]. Finally, little is known about the degree of revers-
ibility of these adverse reactions upon treatment discontin-
uation. The pharmacovigilance study within PERS is aimed
at filling in the safety knowledge gap, through conducting an
observational open-label study in which 600 children and
adolescents aged between 5 and 16 years who have been
prescribed risperidone will be followed over a treatment
period of up to 2 years and comparing them to 250 controls.
If there has been previous use of risperidone, children can
also enter the study as long as there has been no use of
risperidone for the past 6 months. The study will be able to
detect a difference in the rates of clinically significant weight
gain over the first year of usage, defined as an increase in
BMI standardised score of 0.5 or greater. We plan to follow
600 patients under medication and this will allow detection
of an increase from 3 per 100 to 8 per 100 with 90 % power.
The study has further 95 % power to detect rare adverse
events, i.e. with an incidence rate as low as 0.5 per cent. All
participating patients will be regular referrals to child and
adolescent psychiatry centres. There will be no restrictions
for the reasons of prescribing risperidone, both labelled and
unlabelled indications will be included. Also, any possible
concomitant medication will be allowed. The pharmaco-
vigilance study will be fully embedded within regular clin-
ical practice and will solely collect data from patients’
medical records, without imposing any impact on choice and
duration of treatment. Participating clinical centres have
therefore agreed on systematic safety monitoring, in accor-
dance with international recommendations [25].
Main objectives of the PERS pharmacovigilance study
are to follow the course of BMI, waist circumference and
biological parameters and to systematically collect the
frequency, nature, and course of subjectively reported
possible side effects. Subjects will be enrolled at the start
of risperidone treatment. The PERS pharmacovigilance
study includes clinical and/or laboratory parameters prior
to and after 1, 2, 3, 6, 12, 18, and 24 months of treatment
will be collected. Subjectively reported possible side
effects, including those related to suicidality and sexuality
will be collected. Blood laboratory parameters include
glycosylated haemoglobin A1, liver enzymes, fasting lipids
(triglycerides, total cholesterol, HDL cholesterol, LDL
cholesterol); fasting blood glucose; fasting insulin; and
prolactin (see supplementary information for details about
Schedule of Events).
We will also investigate moderating and/or mediating
factors of the short- and long-term adverse events and
changes in weight and waist circumference. Specifically,
we will examine the influence of (1) medication factors
(average daily dose; cumulative dosage of risperidone; pre-
Eur Child Adolesc Psychiatry
123
treatment history of medication; use of concomitant med-
ication; duration of treatment; discontinuation versus con-
tinued use); (2) patient characteristics (age; Tanner stage;
initial BMI/waist circumference; socioeconomic status;
clinical efficacy; clinical indication), and (3) lifestyle fac-
tors including dietary factors, levels of physical activity,
and illicit drug use.
A hierarchical linear regression model will be used to
compare the BMI standardised scores over time with
adjustment for the correlations between assessments within
the same individual. Similar models will be used to identify
patterns that may be associated with drug usage for the
secondary outcomes.
Secondary and exploratory studies on moderating
factors
In addition to examining main treatment effects, it is
important to also examine the impact of potential moder-
ating factors of efficacy and safety. Moderators are char-
acteristics of subjects before treatment that have an impact
on efficacy or tolerability.
An important topic is the subtyping of aggressive and
antisocial behaviour. Among children and adolescents who
develop severe patterns of aggressive and antisocial behav-
iour, there are certain subgroups that may be subject to dis-
tinct causal processes that result in their problem behaviour.
Specifically, callous-unemotional (CU) traits (e.g. lack of
guilt, absence of empathy, callous use of others) are rela-
tively stable and are associated with more severe conduct
problems, delinquency, or aggression. Children and adoles-
cents with CD with and without CU traits also differ in their
emotional, cognitive, and personality characteristics [50].
Another important distinction has been made between
reactive forms of aggression (e.g. in response to perceived
provocation or treat) and instrumental aggression (e.g. pre-
meditated aggression for some gain or reward) [51]. Post
hoc, we will examine whether risperidone differentially
affects CD with and without CU traits, and instrumental
versus affective aggression in both CONCA and DIS-
CONCA trials. We will also examine the role of co-occuring
ADHD, because children with CD and with concurrent
ADHD have an earlier onset of CD and a worse outcome
compared to children with CD without ADHD [52]. Mod-
erators of the short- and long-term adverse events occurring
during risperidone treatment will also be analysed in the
observational pharmacovigilance study.
Ethical considerations
PERS has formed an ethics working group which aims: (1)
to guarantee that ethical standards defined by international
guidelines and national legislations are adhered to and, (2)
to conduct empirical research on ethical issues arising
around PERS. Ethical problems related to research with
children, a so-called vulnerable population, have been
poorly studied. Legislative ethical guidelines [e.g. Inter-
national Conference on Harmonisation (ICH) of technical
requirements for registration of pharmaceuticals for human
use and Good Clinical Practice, (GCP), EU Regulation
1901/2006] implemented in the US and Europe aim to
safeguard children in clinical research and also to facilitate
research with this group. Study-specific ethical issues for
PERS include (1) the placebo design, i.e. has the placebo
group been withheld from receiving an effective treat-
ment?, (2) how can a valuable informed consent/assent of
minors be guaranteed? and (3) the guarantee of only min-
imal harm and burden in the study (are additional blood-
taking and study examinations acceptable to the children?).
Training
Consistent and simultaneous study performance across
several European countries with different nationalities and
languages require standard operation procedures (SOPs).
The study personnel are required to comply with GCP
guidelines, be equipped with clear instructions and feel safe
concerning all relevant procedures. As a key condition for
successful study conduct, a common standard of rating has
to be ensured. This requires a clear structured and har-
monised training programme for both junior and senior
study personnel across the various countries and study
sites. To facilitate inter-site contact, to introduce the study
procedures and to train all involved researchers and pro-
fessional groups (physicians, psychologists, nurses, CROs),
we organised training workshops over a 2-year period.
These had a consistent content to ensure that the study
protocols and procedures were reliably taught to study
personnel.
Training sessions aimed to reach consistent inter-rater
reliability across sites in the application of the Nisonger
Child Behaviour Rating Form, relevant to decisions about
study participation (a D score of at least 27 is mandatory)
and used as the primary outcome measure. Therefore, three
case vignettes were developed and two of them were sent
to the participating centres prior to the workshop, with the
request to rate them and to compare the ratings with the
suggested ‘‘expert’’ rating by the Ulm group. During the
workshop, the third videotape was used to assess agree-
ment on each item and the resulting subscales. Results for
the 18 raters showed that mean value of the D score was
35.4 (SD = 4.75; range 27–45). Eight raters (44.4 %) were
in the range of 34–37 and four had a score of exactly 35,
which is also the ‘‘expert score’’. As the designated
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proceedings concerning adverse events (AE) are corre-
sponding to ICH GCP guidelines, no extra checking in
addition to the one by the monitor was planned.
The rating standards have been documented in booklets,
and are also available as downloadable pdf documents on
the restricted area of the project website. Annual repetition
of training workshops is scheduled both to maintain the
awareness of the procedures among previously trained staff
and train new incoming personnel.
Discussion
As a consequence of the significant burden on the patient,
family and immediate environment and the strong associ-
ations with adverse scholastic and work performance, dis-
rupted peer and family relationships, excessive risk-taking
behaviours and addictive behaviours, CD is a matter of
significant public health and societal concern [53, 54].
Although behavioural parent training programmes have
been shown to have some effects in children and other
psychological treatment approaches may be promising for
adolescents with CD [17], there is an urgent need for fur-
ther evidence-based effective behavioural and pharmaco-
logical treatments for CD in children and adolescents.
More effective treatments will have the potential to not
only prevent the negative personal consequence of CD and
increase both personal productivity and contribution to
society, but could also reduce the burden of CD on the
family and society. Whilst risperidone is often prescribed
off-label for CD, there is a clear need to provide evidence
for its use in youth with CD and normal IQ. PERS studies
will also provide support to professional bodies developing
guidelines for diagnosis and treatment of CD. Furthermore,
it is anticipated that PERS will address several scientific
questions about the moderating and/or mediating factors of
the short-term efficacy and maintenance of clinical
response, and the short-term and long-term safety of ris-
peridone in children and adolescents with CD. In turn,
better understanding of these moderating and mediating
factors will help clinicians make evidence-based decisions
in the consultation room.
Strengths and challenges in PERS
PERS is an academic project financed by the European
Union, involving expert centres in child and adolescent
psychopharmacology all over Europe that collaborates
through the European College of Neuropsychopharmacol-
ogy (ECNP) child and adolescent network. While the
paediatric regulations implemented in US and Europe have
been an important step for the development of research in
child and adolescent neuropsychopharmacology,
involvement of professional networks and associations is
crucial for the implementation of research and training in
academic settings. Recent examples of this support are the
creation of the ECNP school of child and adolescent neu-
ropsychopharmacology and specialised workshops and
expert meetings during ECNP congresses [2]. Therefore,
the goals of this collaborative project extend beyond the
broadening of approved indications of risperidone and also
include a series of issues that are important for treatment
optimization. The latter include the identification of risk
factors for metabolic side effects, the effects of risperidone
on cognitive performance and long-term safety of risperi-
done in CD and in other chronic conditions such as autism
and schizophrenia.
We also expect that PERS will have impact on research
in paediatric psychopharmacology by establishing a col-
laborative network of expert centres, based on the ECNP
child and adolescent neuropsychopharmacology network
(www.ecnp.eu), and that the dissemination of results will
lead to improve standards of care through the development
of assessments and guidelines. Although CD requires
multidisciplinary and social interventions, providing safe
and effective medications for the treatment of CD is
expected to lower the burden of this condition on indi-
viduals, family and society.
PERS, however, is not without challenges. The regula-
tory framework is tight and complex, and the regulatory
requirements and associated timelines are difficult to rec-
oncile with the straightforward time planning of milestones
and deliverables in a typical EU grant. Specifically, the
need to obtain approval from all national regulatory bodies
and ethics commissions was source of unexpected delays
and called for numerous revisions of the study protocol.
This point makes it also difficult to consider any changes or
amendments once the protocol has been approved, because
any further delays will impact the feasibility of patient
recruitment and available budget. Furthermore, budget has
to be allocated for a supporting infrastructure that involves
a Contract Research Organization (CRO), a clinical trial
database, a central lab and ECGs, and central management
of drug supply and logistics. Future non-commercial clin-
ical trials with EU funding will need to take all these into
account. It should also be noted by the European Com-
mission that the budget to run clinical trial with sufficient
quality should be larger than it is at present.
Last but not least, we have to face the difficulties in
recruiting a sufficient number of patients and their families
for the clinical studies. CD populations are relatively
understudied in clinical studies and trials compared to, for
example, ADHD populations. Many children with CD are
not willing to follow a treatment and in a high percentage
of cases have significantly disrupted family and social
backgrounds; therefore, getting informed consent and
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ensuring compliance is likely to be a significant issue. A
common observation is that CD is relatively underdiag-
nosed in mental health settings, due to fear for social
stigma, and instead a less-stigmatised diagnosis of ODD is
conferred. PERS will be instrumental in putting CD higher
at the research agenda in Europe and activating clinicians
and mental health professionals in recognising, diagnosing
and treating CD.
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